Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer
Abstract
177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving 177Lu-PSMA radioligand therapy for castration-resistant prostate...
Paper Details
Title
Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer
Published Date
May 14, 2021
Pages
jnumed.120.258533 - jnumed.120.258533
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History